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SS4.
Open Common Femoral Artery Endarterectomy for Lower Extremity
Ischemia: Predicting the Need for Distal Limb Revascularization
Rafael D Malgor, Joseph J Ricotta, II, Gustavo S Oderich, Manju Kalra,
Thomas C Bower, Audra A Duncan, Peter Gloviczki. Division of Vascular
and Endovascular Surgery, Mayo Clinic, Rochester, MN
Objective: To evaluate the outcomes of open common femoral end-
arterectomy (OCFE) and define predictive factors for additional distal
revascularization.
Methods: We reviewed 230 consecutive patients treated with OCFE
(262 limbs) for lower extremity ischemia between 1997 and 2008. Patients
were divided into two groups: OCFE alone (Group A, 169 limbs), or OCFE
 distal revascularization (Group B, 93 limbs). Iliac disease in both groups
was treated by endovascular approach. End-points were mortality, patency,
re-intervention and limb salvage.
Results: Demographics, clinical severity scores, TASC II classification,
and number of iliac interventions were similar in both groups, but Group B
patients had more (p.001) critical limb ischemia (Rutherford Category
[RC] 51.4 vs 31.2) and diabetes (52% vs 33%). Technical success was
obtained in all patients. In patients with RC 1-4 and RC 5 with TASC A-C
lesions, clinical improvement (99% vs 100%) and limb salvage (99% and
100%) were similar for both groups, but Group B patients had higher
re-intervention rates (14% vs 3%; p0.01). For patients with more advanced
disease (RC 5 with TASC D lesions or RC 6 regardless of TASC) distal
revascularization (Group B) was associated with fewer (p.001) re-inter-
ventions (24% vs 46%) and major amputations (5% vs 29%). Overall 1- and
5-year primary patency rates for OCFE were 97% and 94%, with 100%
secondary patency at both time points. Overall survival was 93% at 1 year and
77% at 5 years. There was no difference in survival between the two groups
for RC 1-5 (p0.2), but for patients with RC 6, survival was improved in
Group B (67% vs 39%; p.09). Independent predictors for distal revascu-
larization are listed in Table 1.
Conclusion: OCFE alone is sufficient for patients who present with
claudication or rest pain regardless of TASC lesion and with RC 5 and TASC
lesions A-C. Distal revascularization should be considered in diabetics, and
in patients with RC 5 and TASC D lesions and those with major tissue loss
(RC 6) regardless of the extent of distal disease.
Table 1. Independent predictors for distal
revascularization
Odds ratio/95% CI
amputation reintervention
Rutherford 5/TASC D 2.6 (0.8-8.8) 5.9 (2.1-16.8)*
Rutherford 6 8.6 (2.44-30.6)* 8.9 (2.1-37.3)*
Diabetes Mellitus
¥
4.3 (1.1-16)* 4.1 (1.4-12.1)*
Chronic Renal Failure
§
2.1 (0.7-2.8)* 2.9 (1.1-7.8)*
Anticoagulation (warfarin) 0.5 (0.06-4.1) 5.3 (1.7-16.1)*¥Insulin Regimen is an independent predictor for distal revasc. (OR2.3
1.1-11; p.02).
§Increased Risk of Amputation for patients on dialysis (OR5.9 1.4-25
p.001).
*p.05.
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SS5.
Soluble Inflammatory and Cellular Adhesion Molecules Predict Mor-
tality, Cardiovascular events (MACE), and Amputation-Free Survival
(AFS) in Patients Undergoing Lower Extremity Vein Bypass Surgery
Christopher D Owens1, Ji Min Kim1, Nathanael D Hevelone1, Allan D
Hamdan2, Joseph D raffetto3, Mark A Creager4, Michael S Conte1. 1UCSF,
San Francisco, CA; 2Beth Israel Deaconess Medical Center, Boston, MA;
3West Roxbury Veteran’s Affairs Medical Center, Boston, MA; 4Brigham
and Women’s Hospital, Boston, MA
Objective: The long term benefits of lower extremity revascularization
(LER) are limited by cardiovascular complications. This study was designed
to test the hypothesis that baseline measures of systemic inflammation are
predictive of postoperative outcomes following open surgical LER.
Methods: Prospective, three-center, cohort study of subjects (N225)
undergoing LER using autogenous vein bypass. Exclusion criteria included
the presence of major infection or systemic illness. Baseline biomarkers
(including high-sensitivity C-reactive protein (hsCRP), vascular cellular
adhesion molecule (VCAM), and interleukin 6 (IL-6)) were obtained prior
to surgery in the fasting state. The main outcomes were mortality, AFS,
MACE, and graft patency. Correlation (Spearman) and Cox proportional
hazard analyses were performed.
Results:Themedian follow up time was 29 14.6months. Indication
for bypass was critical ischemia (CLI) in 129 cases (57%). The median
hs-CRP, VCAM, and IL-6 levels for the entire cohort were 2.98 mg/l,
706.4 ng/ml, and 4.7 pg/mL; these three biomarkers were significantly
correlated with each other (r values 0.39-0.66, p0.05) and with the
presence of CLI (p0.05). All biomarkers evaluated by tertile or upper limit
of reference range. After adjustment for age, diabetes, end-stage renal
disease and tissue loss, all three inflammatory biomarkers were significantly
associated with survival and AFS, particularly in the CLI cohort (Table).
Biomarkers were also independently predictive of MACE. Baseline hsCRP
had a strong univariate association with graft patency (p.010), however
this relationship was attenuated after adjustment for CLI, type of venous
conduit, and outflow level.
Conclusion: Baseline measures of systemic inflammation and cellular
adhesion were independently predictive of mortality, cardiovascular events
and limb-related outcomes following surgical LER. The efficacy of treat-
ments that reduce inflammation should be explored in future investigations.
Adjusted hazard ratios (95% CI) for study outcomes
Overall cohort
(N225) CLI (N129)
Survival
Endpoints N (%) 47 (21.1%) 37 (28.9%)
*CRP (HR, CI) 2.77 (1.41-5.46) 3.81 (1.63-8.93)
VCAM 1.53 (.95-2.47) 2.33 (1.24-4.38)
IL-6 1.78 (1.11-2.85) 2.83 (1.46-5.49)
MACE
Endpoints N(%) 43 (19.3%) 31 (24.2%)
*CRP (HR, CI) 2.30 (1.15-4.59) 2.10 (.95-4.6)
VCAM 1.45 (.90-2.33) 1.86 (1.02-3.38)
IL6 1.28 (.81-2.01) 1.69 (.96-2.99)
AFS
Endpoints N(%) 56 (21.1%) 45 (35.2%)
*CRP (HR, CI) 2.38 (1.31-4.32) 2.97 (1.46-6.02)
VCAM 1.51 (.99-2.32) 2.04 (1.19-3.47)
IL6 1.76 (1.16-2.67) 1.72 (1.10-2.71)
Primary patency
Endpoints N(%) 73 (32.7%) 48 (37.5%)
*CRP (HR, CI) 1.44 (.87-2.40) 1.15 (.63-2.11)
VCAM .90 (.65-1.24) .85 (.57-1.25)
IL6 1.08 (.80-1.47) 1.23 (.85-1.78)*Dichotomized by upper limit of reference range (5 mg/L).
